Amneal Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Amneal Pharmaceuticals (AMRX) to Overweight from Neutral with a price target of $12, up from $9. The firm cites the Crexont ...
Amneal launches Mesalamine; receives U.S. FDA Lenalidomide approval
Amneal Pharmaceuticals (AMRX) announced the launch of mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for the treatment ...
Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide
Mesalamine 800 mg delayed-release tablets, referencing ASACOL HD ® - Lenalidomide capsules, referencing REVLIMID ® BRIDGEWATER, N.J., February 19, 2025--(BUSINESS WIRE)--Amnea ...